Fairvalue-Calculator Fairvalue-Calculator
EN DE

RAY Co (228670) Fair Value & Analysis

Healthcare · KR · Market cap 70.5B KRW

Price4,350 KRW
Fair Value4,425 KRW
Upside+1.7%
Quality94/100
Evidence: High Range 3,658 KRW – 5,531 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

RAY Co (228670) currently trades at 4,350 KRW, while our model-based Fair Value estimate is 4,425 KRW — implying the stock looks roughly 1.7% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry. The company offers RAYSACN Series, RAYios, RAYFace, RAYDENT Microscan, RIO Series, RAYDENT designer and tray, RAYSmiler, RAYDENT Studio, and RAYDENT Mill 4X and 5X, as well as consumables. RAY Co., Ltd. was incorporated in 2004 and is headquartered in Seongnam-si, South Korea.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is RAY Co (228670) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 4,425 KRW versus a price of 4,350 KRW — about +2% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 228670?
Our 21-model fair value for RAY Co is 4,425 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 4,350 KRW.
What is the quality score of 228670?
RAY Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.